瑞替普酶静脉溶栓治疗急性脑梗死的研究进展

Advances in the Treatment of Acute Cerebral Infarction by Intravenous Thrombolysis with Reteplase

目的评价瑞替普酶静脉溶栓治疗脑梗死的疗效的安全性。方法检索中国学术期刊全文数据库、维普数据库、中国生物医学数据库、万方数据库、PubMed,检索时间为建库至2019年5月,收集瑞替普酶溶栓治疗急性脑梗死的临床研究,对相关文献进行系统综述。结果经过检索、筛选共纳入文章35篇,与其他溶栓药物治疗方法相比,瑞替普酶疗效相当,颅内出血、远期死亡风险未明显增加;与常规药物治疗方法相比,瑞替普酶溶栓治疗临床效果明显较好,临床获益显著增加。结论瑞替普酶静脉溶栓治疗急性脑梗死临床疗效较好,且安全性良好。为该药治疗急性脑梗死提供循证参考。

Objective To evaluate the efficacy and safety of reteplase intravenous thrombolysis for cerebral infarction.Methods CNKI,WeiPu,Chinese biomedical database,WanFang and PubMed were searched from the database establishment to May 2019.Clinical studies on reteplase thrombolytic therapy for acute cerebral infarction were collected and relevant literatures were systematically reviewed.Results A total of 35 articles were included after retrieval and screening.Compared with other thrombolytic drugs,reteplase had similar efficacy,but no significant increase in intracranial hemorrhage and long-term death risk.Compared with unthrombolytic therapy,the clinical effect of reteplase thrombolytic therapy was significantly better.Although the bleeding rate increased slightly,there was no significant increase in severe intracranial hemorrhage and long-term mortality.Conclusion Reteplase intravenous thrombolysis for acute cerebral infarction is effective and safe.To provide evidence-based reference for the treatment of acute cerebral infarction.